Study title:
A European and Canadian multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 in patients with stable angina
Date receipt dossier:
11 juil 2002
Pharmaceutical study code:
305602
Company / Sponsor:
Schering N.V./S.A.
Phase:
IIb/III
Treated organism:
Humans
Indication category:
Cardiovascular therapy
Disease:
Chronic angina pectoris
Therapeutic approach:
Gene therapy
Genetic modification:
human FGF-4
Method of transfer of nucleic acid of interest:
Human Adenovirus serotype 5
Administered biological material:
Recombinant Adenovirus D (E1A, E1B)
Route of administration:
Intracoronary
Locations in Belgium:
Universitair Ziekenhuis Gasthuisberg, Leuven - O.-L.-Vrouwziekenhuis, Aalst
Type of procedure:
Contained use only
Current status:
Authorized